

Sandesh Cs Nagamani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12108681/publications.pdf>

Version: 2024-02-01

28
papers

1,231
citations

567281

15
h-index

526287

27
g-index

28
all docs

28
docs citations

28
times ranked

1927
citing authors

#	ARTICLE	IF	CITATIONS
1	Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis. <i>Nature</i> , 2015, 527, 379-383.	27.8	271
2	Urea Cycle Dysregulation Generates Clinically Relevant Genomic and Biochemical Signatures. <i>Cell</i> , 2018, 174, 1559-1570.e22.	28.9	183
3	Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. <i>Journal of Clinical Investigation</i> , 2014, 124, 491-498.	8.2	140
4	Argininosuccinate lyase deficiency. <i>Genetics in Medicine</i> , 2012, 14, 501-507.	2.4	83
5	Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate. <i>Hepatology</i> , 2013, 57, 2171-2179.	7.3	83
6	Induction of Nitric-Oxide Metabolism in Enterocytes Alleviates Colitis and Inflammation-Associated Colon Cancer. <i>Cell Reports</i> , 2018, 23, 1962-1976.	6.4	51
7	Argininosuccinate Lyase Deficiency Causes an Endothelial-Dependent Form of Hypertension. <i>American Journal of Human Genetics</i> , 2018, 103, 276-287.	6.2	39
8	Nitric oxide modulates bone anabolism through regulation of osteoblast glycolysis and differentiation. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	39
9	Glycerol phenylbutyrate treatment in children with urea cycle disorders: Pooled analysis of short and long-term ammonia control and outcomes. <i>Molecular Genetics and Metabolism</i> , 2014, 112, 17-24.	1.1	38
10	A metabolic link between the urea cycle and cancer cell proliferation. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1127314.	0.7	36
11	Acid-Induced Downregulation of ASS1 Contributes to the Maintenance of Intracellular pH in Cancer. <i>Cancer Research</i> , 2019, 79, 518-533.	0.9	36
12	A multicenter study to evaluate pulmonary function in osteogenesis imperfecta. <i>Clinical Genetics</i> , 2018, 94, 502-511.	2.0	33
13	A randomized controlled trial to evaluate the effects of high-dose versus low-dose of arginine therapy on hepatic function tests in argininosuccinic aciduria. <i>Molecular Genetics and Metabolism</i> , 2012, 107, 315-321.	1.1	32
14	Targeting TGF- β 2 for treatment of osteogenesis imperfecta. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	26
15	A Multicenter Observational Cohort Study to Evaluate the Effects of Bisphosphonate Exposure on Bone Mineral Density and Other Health Outcomes in Osteogenesis Imperfecta. <i>JBMR Plus</i> , 2019, 3, e10118.	2.7	22
16	ASL Metabolically Regulates Tyrosine Hydroxylase in the Nucleus Locus Coeruleus. <i>Cell Reports</i> , 2019, 29, 2144-2153.e7.	6.4	21
17	Self-reported treatment-associated symptoms among patients with urea cycle disorders participating in glycerol phenylbutyrate clinical trials. <i>Molecular Genetics and Metabolism</i> , 2015, 116, 29-34.	1.1	12
18	Serum Sclerostin Levels in Adults With Osteogenesis Imperfecta: Comparison With Normal Individuals and Response to Teriparatide Therapy. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 307-315.	2.8	12

#	ARTICLE	IF	CITATIONS
19	Oro-dental and cranio-facial characteristics of osteogenesis imperfecta type V. European Journal of Medical Genetics, 2019, 62, 103606.	1.3	11
20	Alterations in non-type I collagen biomarkers in osteogenesis imperfecta. Bone, 2019, 120, 70-74.	2.9	11
21	Pregnancy in women with osteogenesis imperfecta: pregnancy characteristics, maternal, and neonatal outcomes. American Journal of Obstetrics & Gynecology MFM, 2021, 3, 100362.	2.6	11
22	Malocclusion traits and oral health-related quality of life in children with osteogenesis imperfecta. Journal of the American Dental Association, 2020, 151, 480-490.e2.	1.5	9
23	Biomarkers for liver disease in urea cycle disorders. Molecular Genetics and Metabolism, 2021, 133, 148-156.	1.1	8
24	A Multicenter Study of Intramedullary Rodding in Osteogenesis Imperfecta. JBJS Open Access, 2020, 5, e20.00031-e20.00031.	1.5	7
25	Osteogenesis imperfecta tooth level phenotype analysis: Cross-sectional study. Bone, 2021, 147, 115917.	2.9	7
26	Alterations of a serum marker of collagen X in growing children with osteogenesis imperfecta. Bone, 2021, 149, 115990.	2.9	6
27	Widespread disturbance in extracellular matrix collagen biomarker responses to teriparatide therapy in osteogenesis imperfecta. Bone, 2021, 142, 115703.	2.9	4
28	Skeletal disorders. , 2020, , 369-379.		0